-

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, will be presenting at 3 upcoming healthcare conferences.

Forte will be presenting at the Guggenheim 2nd Annual Healthcare Innovation Conference at the InterContinental Boston in Boston MA on Mon, Nov 10 at 3:30-3:55 PM ET.

On Nov. 12 at 2:00-2:20 PM ET, Forte will present at the virtual TD Cowen Immunology and Inflammation Summit.

Additionally on Dec 4 at 11:15-11:35 AM ET, Forte will be presenting at the 8th Annual Evercore Healthcare Conference in Coral Gables FL at the Loews Hotel.

Source: Forte Biosciences, Inc.

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Forte Biosciences, Inc.
Paul Wagner, CEO
investors@fortebiorx.com

Forte Biosciences, Inc.

NASDAQ:FBRX

Release Versions

Contacts

LifeSci Advisors
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Forte Biosciences, Inc.
Paul Wagner, CEO
investors@fortebiorx.com

More News From Forte Biosciences, Inc.

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s B...

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its third quarter 2025 financial results and provided a business update. “We continue to make excellent progress with FB102,” said Forte Biosciences CEO Paul Wagner, PhD. “The US IND is now open and enrolment in the FB102 phase 2 celiac disease (CeD) clinical trial has expanded to US sites with top...

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of equity awards in the form of options to purchase a total of 125,000 shares of comm...
Back to Newsroom